Board of Directors
Richard B. Dorshow, Ph.D. – Chief Scientific Officer and Founder, MediBeacon
Dr. Dorshow is an experienced research physicist and manager with over 25 years in R&D with a focus on developing innovative, business oriented research programs. He established and led the optical diagnostics and therapeutics program at Mallinckrodt, constructed its Intellectual Property (“IP”) position, and is co-inventor on almost all the related IP. Establishment and subsequent development of this program yielded a robust product pipeline. In the process, valuable relationships with external clinicians were developed, validating the program and providing access to key thought leaders and collaborators.
Dr. Dorshow led the development and fortification of the optical diagnostics IP position at Mallinckrodt. He then had the unique opportunity to launch MediBeacon under which he led the acquisition of the technology, market research, patent estate, and other related assets from Mallinckrodt.
Dr. Dorshow completed his Ph.D. work on the characterization of surfactant systems employing light scattering. This produced some of the first results demonstrating critical behavior in multi-component complex fluid systems. After this, he moved immediately into the industry. At British Petroleum, Dr. Dorshow pioneered the development of a noninvasive optical detection technique for the measurement of oil & gas interfacial properties, needed for estimation of the amount of oil extractable from a reservoir.
Dr. Dorshow is currently a member of the American Physical Society, the Optical Society of America, the Society of Molecular Imaging, the Colloid Division of the American Chemical Society, and the International Society for Optics and Photonics known as SPIE. He is a program committee member and session chair for the International Symposium on Biomedical Optics. Dr. Dorshow has authored or co-authored over 70 scientific publications and is an inventor on over 60 issued U.S. patents.
Dr. Dorshow has his bachelor’s degree in physics from the University of Minnesota, Twin Cities, and his Ph.D. in physics from the University of California, Santa Barbara.
Steven J. Hanley, MBA – Chief Executive Officer and Founder, MediBeacon
Mr. Hanley is an experienced global business leader who has managed highly complex pharmaceutical and medical device operations with annual global revenue exceeding $1 billion. As the President of Covidien’s Imaging Solutions business unit, he led a multifunctional organization that included sales, marketing, logistics, manufacturing, as well as research and development.
Internationally, his track record includes numerous new drug and device product introductions and sales force expansion in Eastern Europe, China, and Latin America. Mr. Hanley is experienced working in different cultures and successfully navigating dynamic regulatory environments.
Over his nearly 18 years with the Covidien family of companies, Mr. Hanley developed a large network of business leaders and clinicians to help determine market needs, commercial potential, and product positioning. As a sales leader, he called on radiologists, nuclear medicine physicians, cardiologists, as well as surgeons in specialties including general, orthopedic, and OB/GYN.
Mr. Hanley is Principal and Founder of Neem LLC. Neem was founded in 2009 to focus on startup and entrepreneurial medical device and other life science companies with whom the firm works to bridge the gap between breakthrough technology and commercialization. Mr. Hanley is the Chairman of the Board of Managers for Daya CNS LLC based in St Louis Missouri. In addition, Mr. Hanley currently is on the Advisory Board for Check-Cap, based in Israel and Kogent Surgical LLC based in St Louis Missouri.
Mr. Hanley has his bachelor’s and master’s degrees in business administration from Marquette University.
